P J Casterella1, D J Kereiakes, S R Steinhubl
1Division of Cardiovascular Disease, Scripps Clinic, La Jolla, California, USA. pjc151@home.com
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
This study found significant variability in how patients respond to abciximab during percutaneous coronary intervention (PCI). Many patients achieve effective platelet inhibition with less than the standard dose, suggesting personalized dosing may be beneficial.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: